|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ANO6 |
Gene summary for ANO6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ANO6 | Gene ID | 196527 |
| Gene name | anoctamin 6 | |
| Gene Alias | BDPLT7 | |
| Cytomap | 12q12 | |
| Gene Type | protein-coding | GO ID | GO:0001503 | UniProtAcc | B3KX12 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 196527 | ANO6 | CCI_1 | Human | Cervix | CC | 7.31e-06 | 7.12e-01 | 0.528 |
| 196527 | ANO6 | CCI_3 | Human | Cervix | CC | 1.52e-06 | 6.17e-01 | 0.516 |
| 196527 | ANO6 | LZE4T | Human | Esophagus | ESCC | 5.30e-07 | 3.22e-01 | 0.0811 |
| 196527 | ANO6 | LZE7T | Human | Esophagus | ESCC | 7.88e-03 | 4.37e-01 | 0.0667 |
| 196527 | ANO6 | LZE8T | Human | Esophagus | ESCC | 5.98e-04 | 9.43e-02 | 0.067 |
| 196527 | ANO6 | LZE20T | Human | Esophagus | ESCC | 7.53e-09 | 4.67e-01 | 0.0662 |
| 196527 | ANO6 | LZE22T | Human | Esophagus | ESCC | 2.49e-03 | 1.67e-01 | 0.068 |
| 196527 | ANO6 | LZE24T | Human | Esophagus | ESCC | 1.17e-04 | 2.46e-01 | 0.0596 |
| 196527 | ANO6 | LZE21T | Human | Esophagus | ESCC | 1.11e-02 | 1.70e-01 | 0.0655 |
| 196527 | ANO6 | P1T-E | Human | Esophagus | ESCC | 2.09e-06 | 3.14e-01 | 0.0875 |
| 196527 | ANO6 | P2T-E | Human | Esophagus | ESCC | 4.80e-30 | 5.73e-01 | 0.1177 |
| 196527 | ANO6 | P4T-E | Human | Esophagus | ESCC | 4.55e-49 | 1.13e+00 | 0.1323 |
| 196527 | ANO6 | P5T-E | Human | Esophagus | ESCC | 1.19e-22 | 5.12e-01 | 0.1327 |
| 196527 | ANO6 | P8T-E | Human | Esophagus | ESCC | 7.03e-19 | 4.65e-01 | 0.0889 |
| 196527 | ANO6 | P9T-E | Human | Esophagus | ESCC | 1.49e-07 | 2.54e-01 | 0.1131 |
| 196527 | ANO6 | P10T-E | Human | Esophagus | ESCC | 4.91e-17 | 2.62e-01 | 0.116 |
| 196527 | ANO6 | P11T-E | Human | Esophagus | ESCC | 9.84e-17 | 6.43e-01 | 0.1426 |
| 196527 | ANO6 | P12T-E | Human | Esophagus | ESCC | 2.52e-18 | 3.09e-01 | 0.1122 |
| 196527 | ANO6 | P15T-E | Human | Esophagus | ESCC | 3.05e-10 | 3.26e-01 | 0.1149 |
| 196527 | ANO6 | P16T-E | Human | Esophagus | ESCC | 1.14e-08 | 1.42e-01 | 0.1153 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001603210 | Cervix | CC | viral process | 109/2311 | 415/18723 | 5.40e-15 | 6.46e-12 | 109 |
| GO:004206010 | Cervix | CC | wound healing | 109/2311 | 422/18723 | 1.84e-14 | 1.57e-11 | 109 |
| GO:005170110 | Cervix | CC | biological process involved in interaction with host | 57/2311 | 203/18723 | 1.18e-09 | 1.41e-07 | 57 |
| GO:00321035 | Cervix | CC | positive regulation of response to external stimulus | 95/2311 | 427/18723 | 5.44e-09 | 5.03e-07 | 95 |
| GO:004440310 | Cervix | CC | biological process involved in symbiotic interaction | 71/2311 | 290/18723 | 7.94e-09 | 6.98e-07 | 71 |
| GO:00603267 | Cervix | CC | cell chemotaxis | 73/2311 | 310/18723 | 2.82e-08 | 1.96e-06 | 73 |
| GO:00975298 | Cervix | CC | myeloid leukocyte migration | 56/2311 | 220/18723 | 7.21e-08 | 4.15e-06 | 56 |
| GO:00305957 | Cervix | CC | leukocyte chemotaxis | 57/2311 | 230/18723 | 1.48e-07 | 7.07e-06 | 57 |
| GO:19030349 | Cervix | CC | regulation of response to wounding | 44/2311 | 167/18723 | 6.33e-07 | 2.31e-05 | 44 |
| GO:00509007 | Cervix | CC | leukocyte migration | 78/2311 | 369/18723 | 1.09e-06 | 3.80e-05 | 78 |
| GO:00026857 | Cervix | CC | regulation of leukocyte migration | 50/2311 | 210/18723 | 2.95e-06 | 8.31e-05 | 50 |
| GO:00026888 | Cervix | CC | regulation of leukocyte chemotaxis | 34/2311 | 122/18723 | 3.00e-06 | 8.38e-05 | 34 |
| GO:005087810 | Cervix | CC | regulation of body fluid levels | 78/2311 | 379/18723 | 3.20e-06 | 8.77e-05 | 78 |
| GO:00509203 | Cervix | CC | regulation of chemotaxis | 51/2311 | 223/18723 | 8.03e-06 | 1.86e-04 | 51 |
| GO:00026878 | Cervix | CC | positive regulation of leukocyte migration | 35/2311 | 135/18723 | 1.25e-05 | 2.60e-04 | 35 |
| GO:00325359 | Cervix | CC | regulation of cellular component size | 76/2311 | 383/18723 | 1.66e-05 | 3.21e-04 | 76 |
| GO:00716755 | Cervix | CC | regulation of mononuclear cell migration | 31/2311 | 115/18723 | 1.67e-05 | 3.22e-04 | 31 |
| GO:00610418 | Cervix | CC | regulation of wound healing | 34/2311 | 134/18723 | 2.70e-05 | 4.52e-04 | 34 |
| GO:00301008 | Cervix | CC | regulation of endocytosis | 47/2311 | 211/18723 | 3.65e-05 | 5.82e-04 | 47 |
| GO:00026906 | Cervix | CC | positive regulation of leukocyte chemotaxis | 26/2311 | 94/18723 | 4.85e-05 | 7.34e-04 | 26 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ANO6 | SNV | Missense_Mutation | c.1075N>T | p.His359Tyr | p.H359Y | Q4KMQ2 | protein_coding | tolerated(0.07) | benign(0.067) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ANO6 | SNV | Missense_Mutation | c.595G>C | p.Glu199Gln | p.E199Q | Q4KMQ2 | protein_coding | deleterious(0.02) | benign(0.433) | TCGA-C8-A275-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ANO6 | SNV | Missense_Mutation | rs745465915 | c.361G>A | p.Glu121Lys | p.E121K | Q4KMQ2 | protein_coding | deleterious(0) | benign(0.393) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
| ANO6 | SNV | Missense_Mutation | rs781608617 | c.1259N>A | p.Arg420His | p.R420H | Q4KMQ2 | protein_coding | deleterious(0) | possibly_damaging(0.871) | TCGA-D8-A1JF-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| ANO6 | SNV | Missense_Mutation | c.1976N>C | p.Arg659Thr | p.R659T | Q4KMQ2 | protein_coding | tolerated(0.62) | benign(0) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ANO6 | SNV | Missense_Mutation | novel | c.1953N>A | p.Met651Ile | p.M651I | Q4KMQ2 | protein_coding | tolerated(0.39) | benign(0.044) | TCGA-EW-A1OV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | epirubicin | SD |
| ANO6 | SNV | Missense_Mutation | novel | c.1273N>C | p.Glu425Gln | p.E425Q | Q4KMQ2 | protein_coding | tolerated(0.08) | possibly_damaging(0.593) | TCGA-EW-A3E8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD |
| ANO6 | SNV | Missense_Mutation | novel | c.2048N>C | p.Gly683Ala | p.G683A | Q4KMQ2 | protein_coding | tolerated(0.07) | possibly_damaging(0.678) | TCGA-LL-A441-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| ANO6 | insertion | Frame_Shift_Ins | novel | c.2465_2466insGACCAGCC | p.Asn823ThrfsTer32 | p.N823Tfs*32 | Q4KMQ2 | protein_coding | TCGA-B6-A0IN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | ||
| ANO6 | insertion | Frame_Shift_Ins | novel | c.2466_2467insGGCCAACATGACAA | p.Asn823GlyfsTer34 | p.N823Gfs*34 | Q4KMQ2 | protein_coding | TCGA-B6-A0IN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |